Neutropenic Sepsis in Patients With Non-Small Cell Lung Cancer Treated With Single-Agent Docetaxel and Associated Resource Use in the UK

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-05-25

Study Completion Date

2016-07-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multi-center retrospective observational research study collecting data for participants initiated on docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC) up to 6 years before start of data collection and who have completed/stopped docetaxel treatment at least 30 days prior to data collection. The primary goal of this study is to describe the percentage of participants with at least one neutropenic sepsis (NS) episode following initiation of treatment with single-agent docetaxel. Data will be collected until end of docetaxel treatment plus an additional 30 days to allow for presentation with toxicity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Docetaxel in Non Small Cell Lung Cancer (NSCLC)

NCT00258739

Lung Neoplasms

COMPLETED PHASE2

SCLC on the 2nd Line With Relapsed After Response to Chemotherapy GFPC 01-2013

NCT02738346

Small Cell Lung Cancer

UNKNOWN PHASE3

Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer

NCT01350817

Non Small Cell Lung Cancer

COMPLETED PHASE2

Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)

NCT00174772

Lung Neoplasms

COMPLETED PHASE2

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

NCT05800587

Lung Cancer Small-cell Lung Cancer Non Small Cell Lung Cancer

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort Docetaxel

Participants initiated on docetaxel for the treatment of relapsed non-small cell lung cancer (NSCLC)

No intervention

Intervention Type OTHER

No intervention administered in this study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

No intervention administered in this study

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with locally advanced or metastatic (stage Ill or IV) non-small cell lung cancer (NSCLC)
* Relapsed disease following, or unable to tolerate, at least one line of prior chemotherapy
* Initiated on single-agent docetaxel up to a maximum of 6 years prior to date of collection
* Aged 18 years at date of first docetaxel dose
* Completed or stopped treatment with docetaxel at least 30 days prior to date of data collection